Provided by Tiger Trade Technology Pte. Ltd.

TransMedics Group, Inc.

113.90
+0.18000.16%
Post-market: 115.711.81+1.59%19:52 EDT
Volume:1.79M
Turnover:203.05M
Market Cap:3.89B
PE:23.39
High:115.72
Open:113.72
Low:112.05
Close:113.72
52wk High:156.00
52wk Low:62.23
Shares:34.17M
Float Shares:32.95M
Volume Ratio:1.78
T/O Rate:5.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.87
EPS(LYR):4.87
ROE:54.24%
ROA:7.25%
PB:8.23
PE(LYR):23.39

Loading ...

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Ceribell, Inc. (CBLL)

TIPRANKS
·
Feb 25

Stock Track | TransMedics Group Soars 7.68% in After-Hours Trading on Strong Q4 Results and Upbeat Guidance

Stock Track
·
Feb 25

Transmedics Group Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 25

TransMedics Gr Q4 Adj. EPS $0.57 Beats $0.39 Estimate

Benzinga
·
Feb 25

Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance

Stock Track
·
Feb 25

TransMedics Gr Q4 Sales $160.764M Beat $155.720M Estimate

Benzinga
·
Feb 25

Transmedics Group Shares up 8.51% at $149.51 in Extended Trade Following Results

THOMSON REUTERS
·
Feb 25

TransMedics Q4 net income hits USD 105.4 million on an 83.8 million tax benefit in Q4 2025

Reuters
·
Feb 25

BRIEF-Transmedics Group Q4 EPS USD 2.62

Reuters
·
Feb 25

Transmedics Group Q4 Gross Margin 58%

THOMSON REUTERS
·
Feb 25

TransMedics Reports NASDAQ Inducement Grants to 14 New Employees

Reuters
·
Feb 21

TransMedics Group Inc. Releases Investor Presentation Document

Reuters
·
Feb 18

TransMedics Group to Present at Major Healthcare Investor Conferences

Reuters
·
Feb 18

Earning Preview: TransMedics Group, Inc. this quarter’s revenue is expected to increase by 41.20%, and institutional views are bullish

Earnings Agent
·
Feb 17

Stifel Nicolaus Sticks to Its Hold Rating for TransMedics Group (TMDX)

TIPRANKS
·
Feb 13

TransMedics Group Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Giovanni Cecere

Reuters
·
Feb 13

TransMedics Group Inc. to Release Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 11

TransMedics erhält vollständige FDA-IDE-Zulassung für OCS Heart ENHANCE Trial

Reuters
·
Feb 09

Transmedics Receives Full and Unconditional FDA Ide Approval for Next-Generation Ocs Heart Enhance Trial

THOMSON REUTERS
·
Feb 09

TD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX)

TIPRANKS
·
Feb 06